MedTrace Logo

Gallium-68 Prostate Specific Membrane Antigen PET in Diagnosing Patients With Thyroid Cancer

NCT03463889 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2021-06-29

Study results available
· View outcomes & findings →

Summary

This pilot clinical trial studies how well Gallium-68 prostate specific membrane antigen positron emission tomography (PET) work in diagnosing patients with thyroid cancer. Diagnostic procedures, such as 68Ga-PSMA PET, may more accurately diagnose thyroid cancer and find out how far the disease has spread.

Conditions

  • Thyroid Gland Carcinoma

Interventions

DRUG

Gallium Ga 68-labeled PSMA-11

Given IV

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI in combination with PET

PROCEDURE

Positron Emission Tomography (PET)

Undergo PET in combination with MRI

Sponsors & Collaborators

Principal Investigators

  • Robert Flavell, MD, PhD · University of California, San Francisco

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-19
Primary Completion
2020-09-30
Completion
2020-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03463889 on ClinicalTrials.gov